Download PDF
Planta Med 2010; 76(10): 981-986
DOI: 10.1055/s-0029-1240884
Pharmacology
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Synephrine and β-Phenethylamine on Human α-Adrenoceptor Subtypes

Guoyi Ma1 , Supriya A. Bavadekar2 , Brian T. Schaneberg1 , Ikhlas A. Khan1 , 3 , Dennis R. Feller1 , 2
  • 1The National Center for Natural Products Research, The University of Mississippi, University, USA
  • 2Department of Pharmacology, School of Pharmacy, The University of Mississippi, University, USA
  • 3Department of Pharmacognosy, School of Pharmacy, The University of Mississippi, University, USA
Further Information

Publication History

received Nov. 21, 2009 revised January 15, 2010

accepted January 21, 2010

Publication Date:
09 March 2010 (online)

    Permissions and Reprints

Abstract

Synephrine and β-phenethylamine, two naturally occurring compounds, are structurally related to ephedrine. In this study, the effects of synephrine and β-phenethylamine on α-adrenergic receptor (α-AR) subtypes are investigated in human embryonic kidney (HEK293) or Chinese hamster ovary (CHO) cells, and compared to that of 1R,2S-norephedrine. The rank order of binding affinities was found to be the same for the subtypes tested (α 1A-, α 2A-, and α 2C-AR) viz, 1R,2S-norephedrine > β-phenethylamine > synephrine. Functional studies on the α 1A-AR subtype showed that synephrine was a partial agonist giving a maximal response at 100 µM that was equal to 55.3 % of the L-phenylephrine maximum. In contrast, neither 1R,2S-norephedrine nor β-phenethylamine exhibited agonist activity at the highest concentration tested (300 µM). β-Phenethylamine was more potent as an antagonist than 1R,2S-norephedrine and synephrine on the α 1A-AR subtype. Functional studies on the α 2A- and α 2C-AR subtypes indicated that synephrine and β-phenethylamine did not act as agonists. Similar to 1R,2S-norephedrine, both of these analogs reversed the effect of medetomidine against forskolin-induced cAMP elevations at 300 µM, and the rank order of antagonist potency was: 1R,2S-norephedrine = β-phenethylamine > synephrine; and β-phenethylamine > 1R,2S-norephedrine > synephrine, respectively. These differences suggest that the presence of a 4-hydroxy group, as in synephrine, reduced the potency in these subtypes. In conclusion, at the α 1A-AR, synephrine acted as a partial agonist, while β-phenethylamine did not exhibit any direct agonist activity. Both, synephrine and β-phenethylamine, may act as antagonists of pre-synaptic α 2A/2C-ARs present in nerve terminals.

Key words

synephrine - β‐phenethylamine - α‐adrenoceptors - partial agonist - radioligand binding assay - cyclic‐AMP

References

  • 1 Griffth R K, Johnson E A. Adrenergic drugs. Foye WO, Lemke TL, Williams DA Principles of medicinal chemistry. Baltimore; Williams & Wilkins 1995: 345-365
    PubMedGoogle Scholar
  • 2 Kalix P. The pharmacology of psychoactive alkaloids from Ephedra and Catha.  J Ethnopharmacol. 1991;  32 201-208
    CrossrefPubMedGoogle Scholar
  • 3 Hoffman B B. Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists, Chapter 10. Hardman JG, Limbird LE Goodman and Gilman's pharmacological basis of therapeutics. New York; McGraw Hill Publishers 2001: 237
    PubMedGoogle Scholar
  • 4 Chua S S, Benrimoj S I. Non-prescription sympathomimetic agents and hypertention.  Med Toxicol Adverse Drug Exp. 1988;  3 387-414
    PubMedGoogle Scholar
  • 5 Arch J R, Ainsworth A T, Cawthorne M A, Piercy V, Vennittt M V, Thody V E, Wilson C, Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs.  Nature. 1984;  309 163-165
    CrossrefPubMedGoogle Scholar
  • 6 Liu Y L, Toubro S, Astrup A, Stock M J. Contribution of β3-adrenergic activation to ephedrine-induced themogenesis in humans.  Int J Obes Relat Metab Disord. 1995;  19 678-685
    PubMedGoogle Scholar
  • 7 Haller C A, Benowitz N L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing Ephedra alkaloids.  N Engl J Med. 2000;  343 1833-1838
    CrossrefPubMedGoogle Scholar
  • 8 Josefson D. Herbal stimulant causes US deaths.  BM J. 1996;  312 1378-1379
    PubMedGoogle Scholar
  • 9 Trendelenburg U. Supersensitivity and subsensitivity to sympathomimetic amine.  Pharmacol Rev. 1963;  15 225-276
    PubMedGoogle Scholar
  • 10 Trendelenburg U, Gomez Alonso de la Sierra B, Muskus A. Modification by reserpine of the response of atrial pacemaker to sympathomimetic amines.  J Pharmacol Exp Ther. 1963;  141 301-309
    PubMedGoogle Scholar
  • 11 Haaz S, Fontaine K R, Cutter G, Limdi N, Perumean-Chaney S, Allison D B. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update.  Obes Rev. 2006;  7 79-88
    CrossrefPubMedGoogle Scholar
  • 12 Brown C M, McGrath J C, Midgley J M, Muir A G B, O'Brien J W, Thonoor C M, Williams C M, Wilson V G. Activities of octopamine and synephrine stereoisomers on α-adrenoceptors.  Br J Pharmacol. 1988;  93 417-429
    PubMedGoogle Scholar
  • 13 Jordan R, Midgley J M, Thonoor C M, Williams C M. β-Adrenergic activities of octopamine and synephrine stereoispmers on guinea-pig atria and trachea.  J Pharm Pharmacol. 1987;  39 752-754
    CrossrefPubMedGoogle Scholar
  • 14 Kim K W, Kim H D, Jung J S, Woo R S, Kim H S, Suh H W, Kim Y H, Song D K. Characterization of antidepressant-like effects of α-synephrine stereoisomers.  Naunyn Schmiedebergs Arch Pharmacol. 2001;  264 21-26
    PubMedGoogle Scholar
  • 15 Starke K. A history of Naunyn-Schmiedeberg's archives of pharmacology.  Naunyn Schmiedebergs Arch Pharmacol. 1998;  358 1-109
    CrossrefPubMedGoogle Scholar
  • 16 Sloviter R S, Connor J D, Drust E G. Serotonergic properties of β-phenethylamine in rats.  Neuropharmacology. 1980;  19 1071-1074
    CrossrefPubMedGoogle Scholar
  • 17 Sabelli H C, Javaid J I. Phenylethylamine modulation of affect: therapeutic and diagnostic implication.  J Neuropsychiatry Clin Neurosci. 1995;  7 6-14
    PubMedGoogle Scholar
  • 18 Ma G, Bavadekar S A, Davis Y M, Lalchandani S G, Nagmani R, Schaneberg B T, Khan K A, Feller D R. Pharmacological effects of ephedrine alkaloids on human α1- and α2-adrenergic receptor subtypes.  J Pharmacol Exp Ther. 2007;  322 214-221
    CrossrefPubMedGoogle Scholar
  • 19 Lalchandani S G, Zhang X, Hong S S, Liggett S B, Li W, More B M, Miller D D, Feller D R. Medetomidine analogs as selective agonists for the human α2-adrenoceptors.  Biochem Pharmacol. 2004;  67 87-96
    CrossrefPubMedGoogle Scholar
  • 20 Cheng Y, Prusoff W H. Relationship between the inhibition constant (Ki) and the concentration of the inhibitor, which causes 50 % inhibition (IC50) of an enzymatic reaction.  Biochem Pharmacol. 1973;  22 3099-3108
    CrossrefPubMedGoogle Scholar
  • 21 Vansal S S, Feller D R. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes.  Biochem Pharmacol. 1999;  58 807-810
    CrossrefPubMedGoogle Scholar
  • 22 Rothman R B, Vu N, Partilla J S, Roth B L, Hufeisen S J, Compton-Toth B A, Birkes J, Young R, Glennon R A. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective action as norepinephrine transporter substrates.  J Pharmacol Exp Ther. 2003;  307 138-145
    CrossrefPubMedGoogle Scholar
  • 23 Baker G B, Raiteri M, Bertollini A, Del Carmine R, Keane P E, Martin I L. Interaction of β-phenethylamine with dopamine and noradrenaline in the central nervous system of the rat.  J Pharm Pharmacol. 1976;  28 456-457
    PubMedGoogle Scholar

Dr. Dennis R. Feller

Department of Pharmacology
School of Pharmacy
The University of Mississippi

University, MS 38677

USA

Phone: + 1 66 29 15 12 01

Fax: + 1 66 29 15 51 48

Email: dfeller@olemiss.edu

      >